Table 1 Baseline characteristics of study patients

Age(years)

62.13 ± 11.27

61.79 ± 12.86

0.877

 Male sex, n (%)

186 (81.22)

636 (82.70)

0.605

 Current smokers, n (%)

132 (57.81)

454 (59.11)

0.706

 ^aFamily history, n (%)

32 (13.97)

89 (11.57)

0.329

 Hypertension, n (%)

113 (49.34)

424 (55.14)

0.122

 Diabetes, n (%)

46 (20.31)

185 (24.14)

0.211

 Stroke, n (%)

25 (10.92)

93 (12.09)

0.628

 Dyslipidemia, n (%)

128 (55.89)

414 (53.84)

0.583

 Chronic renal failure, n (%)

10 (4.37)

29 (3.77)

0.683

 ^bPrevious revascularization, n (%)

11 (4.80)

67 (8.71)

0.053

 Previous long-term statin, n (%)

36 (15.72)

91 (11.83)

0.121

 Previous long-term aspirin, n (%)

57 (24.89)

143 (18.59)

0.037

Preinfarct angina within 1 month, n (%)

143 (62.45)

293 (38.10)

0.001

 Time to angiography, hours

5.1[2.7, 7.8]

4.3[2.6, 7.2]

0.212

 SBP, mmHg

124.25 ± 23.07

117.41 ± 21.56

0.018

 DBP, mmHg

76.51 ± 12.59

75.44 ± 12.12

0.067

 Hear rate, beats/min

67.41 ± 11.1

73.12 ± 14.69

0.021

 LVEF, %

58 ± 11

49 ± 10

0.001

 Killip2–4, n (%)

50 (21.83)

161(20.93)

0.770

 Killip3–4, n (%)

21 (7.86)

87 (10.97)

0.359

 IABP use, n(%)

8 (3.49)

80 (10.40)

0.001

 Infarct location, n (%)

0.203

  Anterior

141 (61.57)

429 (55.79)

  Inferior

78 (34.06)

312 (40.57)

  Lateral

10 (4.37)

28 (3.64)

 Aspirin

229 (100%)

769 (100%)

N/A

 Clopidogrel

229 (100%)

769 (100%)

N/A

 GP-IIb/IIIa antagonists

44 (19%)

130 (17%)

0.42

 Heparin

229 (100%)

769 (100%)

N/A

  Primary PCI

145 (63.31)

710 (92.32)

< 0.001

  No revascularization

69 (30.13)

59 (7.67)

< 0.001